Seltene Nebenwirkungen von biologischen DMARD

Zusammenfassung

Die Einführung der Biologika Ende der 1990er-Jahre hat zweifelsohne die Behandlungsmöglichkeiten entzündlich rheumatischer Systemerkrankung nachhaltig verändert, um nicht zu sagen revolutioniert. Zusammen mit der Etablierung von Konzepten zur frühen Diagnose und therapeutischen Intervention sowie Treat-to-Target-Strategien mit dem Ziel der Remission hat sich die Prognose rheumatologischer Patienten erheblich verbessert. Nach nunmehr bis zu 20-jähriger Anwendung in der klinischen Routine kann zudem von einer überwiegend guten Verträglichkeit und Sicherheitsdatenlage der Biologika ausgegangen werden. Dennoch finden sich mitunter seltene unerwünschte Arzneimittelwirkungen. Dieser Artikel beschäftigt sich genau mit den eher selteneren unerwünschten Arzneimittelwirkungen, welche in der klinischen Routine dennoch berücksichtigt werden müssen.

Summary

Advances in the treatment of rheumatic diseases have come both from new approaches to the use of available therapies, particularly strategic concepts to treat early and to treat-to-target, and from the development of novel agents called biological DMARDs (bDMARDs) that more effectively target key elements of the immune response and pathways involved in the disease process beginning in the late 1990s. Despite these undisputed advances, some patients suffer adverse effects. This article discusses rare adverse effects associated with the use of bDMARDs.

Schlüsselwörter

bDMARD - Biologika - Nebenwirkungen - Infektionen

Keywords

bDMARD - biologics - side effects - infections

• Literatur

• 1 Atzeni F, Talotta R, Salaffi F. et al Immunogenicity and autoimmunity during anti-TNF therapy.. Autoimmun Rev 2013; 12: 703-708
• 2 Ramos-Casals M. Roberto-Perez-Alvarez, Diaz-Lagares C. et al Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010; 9: 188-193
• 3 Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. BIOGEAS study group. Biologics-induced autoimmune diseases.. Curr Opin Rheumatol 2013; 25: 56-64
• 4 Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management.. Nat Rev Rheumatol 2014; 10: 612-627
• 5 Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review.. ScientificWorldJournal 2014; 2014 179180
• 6 Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy.. Muscle Nerve 2008; 37: 281-292
• 7 Czaja AJ. Drug-induced autoimmune-like hepatitis.. Dig Dis Sci 2011; 56: 958-976
• 8 Ramos-Casals M, Brito-Zerón P, Muñoz S. et al Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.. Medicine (Baltimore) 2007; 86: 242-251
• 9 De Bandt M, Sibilia J, Le Loët X. et al Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.. Arthritis Res Ther 2005; 7: R545-R551
• 10 Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus.. Rheumatology (Oxford) 2009; 48: 716-720
• 11 Soforo E, Baumgartner M, Francis L. et al Induction of systemic lupus erythematosus with tumor necrosis factor blockers.. J Rheumatol 2010; 37: 204-205
• 12 Harrison MJ, Dixon WG, Watson KD. et al Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.. Ann Rheum Dis 2009; 68: 209-215
• 13 Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.. Semin Arthritis Rheum 2010; 40: 233-240
• 14 Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?. Clin Exp Rheumatol 2012; 30: 700-706
• 15 Wollina U, Hansel G, Koch A. et al Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.. Am J Clin Dermatol 2008; 9: 1-14
• 16 Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M. et al Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.. Am J Med 2011; 124: 386-394
• 17 Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C. et al Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.. Semin Arthritis Rheum 2011; 41: 256-264
• 18 TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.. Neurology 1999; 53: 457-465
• 19 Mohan N, Edwards ET, Cupps TR. et al Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.. Arthritis Rheum 2001; 44: 2862-2869
• 20 Dreyer L, Magyari M, Laursen B. et al Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.. Ann Rheum Dis 2016; 75: 785-786
• 21 Koo S, Marty FM, Baden LR. et al Infectious complications associated with immunomodulating biologic agents.. Infect Dis Clin North Am. 2010; 24 (02) 285-306
• 22 Singh JA, Cameron C, Noorbaloochi S. et al Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.. Lancet 2015; 386 9990 258-265
• 23 Strangfeld A, Eveslage M, Schneider M. et al Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70 (11) 1914-1920
• 24 Wallis RS, Broder MS, Wong JY. et al Granulomatous infectious diseases associated with tumor necrosis factor antagonists.. Clin Infect Dis 2004; 38 (09) 1261-1265
• 25 US Food and Drug Administration. FDA Drug Safety Communication: drug labels for the tumor necrosis factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm
• 26 Lanternier F, Tubach F, Ravaud P. et al Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.. Chest 2013; 144: 990-998
• 27 Winthrop KL, Baddley JW, Chen L. et al Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.. JAMA 2013; 309 (09) 887-895
• 28 McDonald JR, Zeringue AL, Caplan L. et al Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.. Clin Infect Dis 2009; 48 (10) 1364-1371
• 29 Strangfeld A, Listing J, Herzer P. et al Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.. JAMA 2009; 301 (07) 737-744
• 30 Galloway JB, Mercer LK, Moseley A. et al Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.. Ann Rheum Dis 2013; 72 (02) 229-234
• 31 Lee JH, Slifman NR, Gershon SK. et al Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.. Arthritis Rheum 2002; 46 (10) 2565-2570
• 32 Baddley JW, Winthrop KL, Chen L. et al Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.. Ann Rheum Dis 2014; 73 (11) 1942-1948
• 33 Kwon HJ, Coté TR, Cuffe MS. et al Case reports of heart failure after therapy with a tumor necrosis factor antagonist.. Ann Intern Med 2003; 138 (10) 807-811
• 34 Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.. Am J Med 2004; 116: 305-311
• 35 Solomon DH, Rassen JA, Kuriya B. et al Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.. Ann Rheum Dis 2013; 72: 1813-1818
• 36 Ljung L, Askling J, Rantapää-Dahlqvist S. et al The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.. Arthritis Res Ther 2014; 16 (03) R127 doi: 10.1186/ar4584
• 37 Balkwill F. Tumor necrosis factor and cancer.. Nat Rev Cancer 2009; 9: 361-371
• 38 Askling J, Fahrbach K, Nordstrom B. et al Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept and infliximab using patient level data.. Pharmacoepidemiol Drug Saf 2011; 20: 119-130
• 39 Mariette X, Matucci-Cerinic M, Pavelka K. et al Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.. Ann Rheum Dis 2011; 70: 1895-1904
• 40 Dreyer L, Cordtz RL, Hansen IMJ. et al Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.. Ann Rheum Dis 2018; 77 (04) 510-514
• 41 Raaschou P, Söderling J, Turesson C. et al Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis: A Nationwide Population-Based Cohort Study.. Ann Intern Med 2018; 169 (05) 291-299
• 42 Teichmann LL, Woenckhaus M, Vogel C. et al Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis.. Rheumatology (Oxford) 2008; 47: 1256-1257
• 43 Wingfield T, Jani M, Krutikov M. et al Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab.. Rheumatology (Oxford) 2011; 50: 1725-1727
• 44 Vallet H, Houitte R, Azria A, Mariette X. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis.. J Rheumatol 2011; 38: 965-966
• 45 Rutherford AI, Patarata E, Subesinghe S. et al Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.. Rheumatology (Oxford) 2018; 57: 997-1001
• 46 Clifford DB, Ances B, Costello C. et al Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.. Arch Neurol 2011; 68: 1156-1164
• 47 Buch MH, Smolen JS, Betteridge N. et al Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.. Ann Rheum Dis 2011; 70: 909-920
• 48 Pyrpasopoulou A, Douma S, Vassiliadis T. et al Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis.. Rheumatol Int 2011; 31: 403-404
• 49 Tien YC, Yen HH, Chiu YM. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.. Clin Exp Rheumatol 2017; 35: 831-836
• 50 Tesfa D, Ajeganova S, Hägglund H. et al Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.. Arthritis Rheum 2011; 63: 2209-2214
• 51 Salmon JH, Cacoub P, Combe B. et al Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.. RMD Open 2015; 1: e000034
• 52 Schwaneck EC, Renner R, Junker L. et al Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients.. Arthritis Rheumatol 2018; 70 (12) 1914-1922 doi: 10.1002/art.40654. Epub 2018 Oct 30
• 53 Rutherford AI, Subesinghe S, Hyrich KL. et al Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Annals of the Rheumatic Diseases 2018; 77: 905-910
• 54 Pawar A, Desai RJ, Solomon DH. et al Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study Annals of the Rheumatic Diseases 2019; 78: 456-464